Digital Pharma: Boehringer readies ‘diabetes hub’

pharmafile | May 20, 2010 | News story | Medical Communications Boehringer, digital pharma, disease awareness campaigns, patient information 

Boehringer Ingelheim will shortly unveil a ‘digital diabetes hub’ that combines educational videos, research tools, educational games and information on type II diabetes.

Currently undergoing final checks, the new website is due to go live soon at and will be aimed at a European audience.

It is expected to have a wide range of features, include one that offers diabetes sufferers the opportunity to share their story.

The site’s video content will include a short educational animation on the mode of action of DPP-4 inhibitors, and a film that looks at diabetes through the eyes of those who live with the condition.

The Diabetes Health Lounge will be unveiled ahead of the anticipated launch date of Boehringer’s new type II drug diabetes linagliptin.

Boehringer’s new diabetes drug linagliptin

The oral once-daily tablet linagliptin is a member of the DPP-4 inhibitor class, which includes two already approved drugs – MSD’s Januvia (sitagliptin) and Novartis’ Galvus (vildagliptin).

Boehringer’s drug could also threaten older oral diabetes treatments such as GlaxoSmithKline’s Avandia (rosiglitazone) as well as Onglyza (saxagliptin), a newer DPP-4 drug co-marketed by Bristol-Myers Squibb and AstraZeneca.

Dominic Tyer is web editor for Pharmafocus and and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.

Related Content


Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 …


Boehringer withdraws its £700m investment in Hikma Pharmaceuticals

Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the …


Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype

The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment …

Latest content